Related Experiment Video
Updated: Sep 18, 2025
06:38
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
9.0K
Sorafenib with or without co-interventions for hepatocellular carcinoma
Shanshan Chen1, Jian Ping Liu2, Xinyu Li1
1Cancer Center, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
The Cochrane Database of Systematic Reviews
|June 26, 2025
Summary
This review assesses sorafenib for hepatocellular carcinoma in adults. It compares sorafenib, with or without other treatments, against placebo or no intervention to understand its benefits and harms.
Area of Science:
- Hepatology
- Oncology
- Clinical Trials
Background:
- Hepatocellular carcinoma (HCC) is a primary liver cancer with significant global impact.
- Sorafenib is a targeted therapy approved for advanced HCC, but its efficacy and safety profile require ongoing evaluation.
Purpose of the Study:
- To systematically review the beneficial and harmful effects of sorafenib in adults with hepatocellular carcinoma.
- To compare sorafenib, with or without co-interventions, against placebo, no intervention, or identical co-interventions.
Main Methods:
- This is a protocol for a Cochrane Review, adhering to rigorous systematic review methodology.
- The review will synthesize evidence from randomized controlled trials and other relevant study designs.
Main Results:
- Evidence synthesis is pending completion of the review.
- Anticipated results will quantify the efficacy and safety of sorafenib for HCC treatment.
Conclusions:
- The findings will inform clinical decision-making regarding sorafenib use in hepatocellular carcinoma.
- This review aims to provide high-quality evidence for patients and healthcare providers managing HCC.
Related Concept Videos
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
01:11Renal Failure: Dose Adjustments
166
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
166
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
02:49Cancer Therapies
8.0K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.0K
01:16Hepatic Drug Excretion: Influencing Factors
234
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
234
01:25Antihypertensive Drugs: Direct Renin Inhibitors
845
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
845